The Oncoceutics Team:
Wolfgang Oster, MD, PhD - Chairman and CEO
Lee Schalop, MD - Vice Chairman and COO
Joshua Allen, PhD - Senior VP, Research and Development
Sebastian Franzinger, VP Finance and Business Development
Varun Prabhu, PhD - Associate VP Research and Development

Topic: Onc-201 For DIPG and H3 K27M Glioma

Links from the presentation:

• Slide 33: Media reports
  
  • Philadelphia Inquirer: Cancer therapy shows promise for some brain tumors
  • Dana Farber Cancer Institute: First-Of-Its-Kind Treatment Beats Back Notorious Brain Tumor
  • People Magazine: Preschool Teacher with Brain Tumor Who Was Given a Week to Live Is Now Thriving
  • Michigan Health: Brain Cancer Patient Finds Hope with Emerging New Therapy
  • Omaha World-Herald: Experimental drug 'nothing short of miraculous' for father of 4 with super-rarebrain tumor
  • DailyMail UK: Preschool teacher, 30, diagnosed with a rare brain tumor (...) thriving after taking a newclinical trial drug
  
  
• Slide 24: Patient Resources
  
  • List of ONC201 trials
  • Contact information for physicians
  • Contact information for patients and parents
  • Educational information about ONC201 in Neuro-Oncology
  • Scientific information and list of publications